Доцетаксел в лечении гормонорезистентного рака предстательной железы

1. Graft N., Shostac Y., Carey M. et al. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nature Med 1999;5(3):280—5.

2. Green S., Furr B. Prospects for the treatment of endocrine-responsive tumors. Endocr Relat Cancer1999;6(3):349—71.

3. Lein M., Yung K., Dinh L.K. et al. Synthetic inhibitor of metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model. Prostate 2000;43(2):77—82.

4. Petrylak D.P. Chemotherapy for advanced hormone refractory prostate cancer. Urology 1999;54:30—5.

5. Primo L.N., Meyers F.K. Treatment options in androgen-independent prostate cancer. Cancer Invest 1999;17(2):137—44.

6. Rosenthal M.A. Advances in the management of prostate cancer. Aust NZJ Med 2000;30(5):593—9.

7. Eisenberger M.A., De Vit R., Berry W. et al. A multicenter phase III comparison of docetaxel + prednisone and mitoxantrone + prednisone in patients with hormonerefractory prostate cancer. Proc Am Soc Clin Oncol 2004;45:5 (abstr. 4).

8. Petrylak D.P., Tangen C., Hussain M. et al. SWOG 99-16: Randomized phase III trial of docetaxel/estramustine versus mitoxantrone/prednizolone in men with androgen independent prostate cancer. Proc Am Soc Clin Oncol 2004;45:5 (abstr. 3).

9. Ellerhorst J.A., Tu S.M., Amato R.J. et al. Phase II trial of alternating weekly chemogormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res 1997;3:2371—6.